| Literature DB >> 32829954 |
Rupsa C Boelig1, Calvin Lambert2, Juan A Pena3, Joanne Stone3, Peter S Bernstein2, Vincenzo Berghella4.
Abstract
The purpose of this article is to review key areas that should be considered and modified in our obstetric protocols, specifically: 1) Patient triage, 2) Labor and delivery unit policies, 3) Special considerations for personal protective equipment (PPE) needs in obstetrics, 4) Intrapartum management, and 5) Postpartum care.Entities:
Keywords: Epidemic; Obstetric protocols; Pandemic; Public health
Year: 2020 PMID: 32829954 PMCID: PMC7378469 DOI: 10.1016/j.semperi.2020.151295
Source DB: PubMed Journal: Semin Perinatol ISSN: 0146-0005 Impact factor: 3.300
Fig. 1Phone triage flow.
Fig. 2Suggested flow for screening patients presenting to L&D triage.
Special Considerations for Commonly Administered Obstetric Medications
| Drug | Indication | Special Consideration |
|---|---|---|
| Hydralazine | Severe hypertension | Avoid in patients with tachycardia |
| Labetalol | Severe hypertension | Given theoretical concern of beta-blocker causing bronchial constriction in patients with asthma, consider avoiding in these patients with respiratory distress |
| Nifedipine | Severe hypertension/Tocolysis | Risk of worsening hypotension and suppression of heart rate and contractility; avoid in patients with hypotension or preload dependent cardiac lesions |
| Indomethacin | Tocolysis | Avoid if contraindication to NSAID including renal failure. |
| Terbutaline | Tocolysis | Avoid in patients with contraindication for tachycardia |
| Carboprost | Postpartum hemorrhage (PPH) | Avoid given the risk of bronchospasm in patients with underlying respiratory compromise |
| Methylergonovine | PPH | No pandemic specific restrictions outside of normal contraindications |
| Misoprostol | PPH/Induction | No pandemic specific restrictions outside of normal contraindications |
| Magnesium sulfate (MgSO4) | Neuroprotection/Seizure prophylaxis | Respiratory compromise usually seen in levels of 10–13 mg/dL. Take precautions to avoid the development of toxicity, particularly in patients with renal compromise |
| Steroids | Fetal lung maturity | Well established benefit between 24–33 6/7 weeks of gestation; in the setting of critical illness, risks and benefits should be considered before administration. |